Immunotherapy for Advanced HCC: Case Series

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh B liver functionSecond-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumabManagement of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitorPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72

There are no comments yet.

Please log in to write the first comment.